Is Sermorelin Legal in Washington? How to Access It Legally
HealthRX.com
Sermorelin sold today is compounded, not FDA-approved
Key numbers
- 0.05 mgGeref ampule strength, approved only to test the pituitary's growth hormone secretionSource: federalregister.gov, as cited Nov 7, 2026
- 0.5 mgGeref vial strength, approved for idiopathic growth hormone deficiency in children; since withdrawnSource: federalregister.gov, as cited Nov 7, 2026
- 29-amino-acidLength of sermorelin, a GHRH analogue rather than growth hormone itselfSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- FDA-approved today / No — Geref withdrawn in 2009 [1]
- What is sold now / Compounded, not FDA-reviewed [2]
- FDA safety-risk list / Not listed [5]
- Outsourcing-facility nominated list / Category 1, under evaluation [6]
- State-licensed pharmacy and physician list / Not in any category [7]
- Sport / Prohibited at all times [4]
The federal status
Sermorelin acetate was approved twice as Geref, made by EMD Serono: NDA 019863, a 0.05 mg ampule approved December 28, 1990 to test the pituitary's ability to secrete growth hormone, and NDA 020443, 0.5 mg and 1 mg vials approved September 26, 1997 for idiopathic growth hormone deficiency in children with growth failure [1]. The manufacturer discontinued both in 2008 and asked FDA to withdraw the applications; FDA withdrew both effective June 18, 2009 [1]. In March 2013 the agency determined Geref had not been withdrawn from sale for reasons of safety or effectiveness [1][8].
Those two applications are the only sermorelin entries in Drugs@FDA, and both are listed as discontinued [1][8]. Sermorelin products available today are compounded. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [2].
Geref's approved uses were pediatric growth hormone deficiency and a diagnostic test of the pituitary. It was never approved for adults, anti-aging, weight loss or athletic performance [1]. Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone, not growth hormone itself [9].
What Washington law covers
RCW 74.09.325 requires Medicaid managed care organizations to reimburse a provider for a covered service delivered by telemedicine when the same service would be covered in person, is medically necessary, is an essential health benefit and can be safely and effectively delivered that way. Payment is generally the same amount as for in-person care, though hospitals, hospital systems, telemedicine companies and larger provider groups may negotiate a different amount [3]. It is a payment statute, and the text does not address sermorelin [3].
HealthRX.com offers sermorelin by prescription.
Questions worth asking
Where sermorelin sits on FDA's compounding lists
Sermorelin does not appear on FDA's page of bulk drug substances that may present significant safety risks when compounded, content dated 04/22/2026 [5]. On FDA's list of nominated bulk substances for outsourcing facilities, updated March 21, 2025, sermorelin acetate is in category 1, under evaluation, and carries the list's marker for substances that are components of FDA-approved drugs [6]. It appears in no category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [7], and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [10].
Prohibited in sport
WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, and prohibits it at all times, in and out of competition; S2 substances are non-Specified Substances. The 2027 List, in force January 1, 2027, names it again [4][11].
Frequently asked questions
Is sermorelin FDA-approved?
Is sermorelin legal in Washington?
Is sermorelin on FDA safety-risk lists?
Is sermorelin banned in sport?
References
Show all 11 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- RCW 74.09.325.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Official web page.
- World Anti-Doping Agency.